## Case 1

**Table 1** NEXUS chest criteria

| |
|---|
| Age >60 years |
| Rapid deceleration mechanism [fall >6 meters (20 feet) or motorized vehicle accident >65 km (40 miles) per hour] |
| Chest pain |
| Intoxication |
| Distracting injury |
| Tenderness to chest wall palpation |
| Abnormal alertness/mental status |

NEXUS, National Emergency X-radiography Utilization Studies.

Table Title

Table Body

Table Footnote

## Case 2

**Table 2** Clinic trials of checkpoint inhibitor therapy in hepatobiliary cancers

| Agents | Cancer Type | Patient Population | Immunotherapy Target (s) | Phase | ClinicalTrials.gov Locator |
|---|---|---|---|---|---|
| Tislelizumab | HCC | Advanced | PD-1 | Phase III | NCT03412773 |
| Durvalumab and Tremelimumab | HCC | Advanced | PD-L1 and CTLA-4 | Phase III | NCT03298451 |
| Atezolizumab and Bevacizumab | HCC | Advanced | PD-L1 | Phase III | NCT03434379 |
| Pembrolizumab plus lenvatinib | HCC | Advanced | PD-1 | Phase III | NCT03713593 |
| Nivolumab and Ipilimumab | HCC | Advanced | PD-1 and CTLA-4 | Phase III | NCT04039607 |
| Nivolumab | HCC | Adjuvant | PD-1 | Phase III | NCT03383458 |
| Pembrolizumab | HCC | Adjuvant | PD-1 | Phase III | NCT03867084 |
| Durvalumab and Bevacizumab | HCC | Adjuvant | PD-L1 | Phase III | NCT03847428 |
| Durvalumab | BTC | Advanced | PD-L1 | Phase III | NCT03875235 |
| Pembrolizumab | BTC | Advanced | PD-1 | Phase III | NCT04003636 |
| M7824 | BTC | Advanced | PD-L1 | Phase III | NCT04066491 |
| KN035 | BTC | Advanced | PD-L1 | Phase III | NCT03478488 |
| Nivolumab and TACE | HCC | Localized | PD-1 | Phase II | NCT03572582 |
| Nivolumab and Y90 | HCC | Advanced | PD-1 | Phase II | NCT03033446 |

HCC, hepatocellular carcinoma, BTC, biliary tract cancer, TACE, trans-arterial chemoembolization; Y90, Yttrium-90.

Table Title

Table Head

Table Body

Table Footnote

## Case 3

**Table 1** FDA approvals for Immunotherapy in HCC and BTC in United States

| Immunotherapy FDA | HCC | | BTC | | HCC and BTC | |
|---|---|---|---|---|---|---|
| | Approval | Date | Approval | Date | Tumor Agnostic Approval (MSI-high) | Date |
| Nivolumab | Yes | Sep 22, 2017 | No | N/A | No | N/A |
| Pembrolizumab | Yes | Nov 9, 2018 | No | N/A | Yes | May 23, 2017 |

HCC, hepatocellular carcinoma; BTC, biliary tract cancer; N/A, not applicable.

Table Title

Table Head

Table Body

Table Footnote